Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials

NCT05863858 is registered in ClinicalTrials.gov with Iyad Naeem Muhammad, PhD as lead sponsor.

NCT NCT05863858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05863858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials
Lead sponsor
Iyad Naeem Muhammad, PhD
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2020
Completion date
June 8, 2022
Enrollment
162 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection, helicobacter pylori infection, susceptibility to